Welcome to our dedicated page for VAPOTHERM news (Ticker: VAPO), a resource for investors and traders seeking the latest updates and insights on VAPOTHERM stock.
Vapotherm, Inc. (OTCQX: VAPO) is a leading developer and manufacturer of advanced respiratory technology headquartered in Exeter, New Hampshire, USA. The company focuses on creating innovative, comfortable, and non-invasive technologies to support patients with chronic or acute breathing disorders. Over 4.4 million patients globally have benefited from Vapotherm's high-velocity therapy systems, including the HVT 2.0 and Precision Flow systems.
Vapotherm's core product, high-velocity therapy, is a mask-free, non-invasive ventilatory support tool that effectively relieves respiratory distress—including hypercapnia, hypoxemia, and dyspnea. This technology allows for the fast, safe treatment of undifferentiated respiratory distress with a single tool. The mask-free interface delivers optimally conditioned breathing gases, making it more comfortable for patients and reducing the risks associated with traditional mask therapies.
The company has shown significant sales growth and continues to invest in future growth drivers such as the HVT 2.0, clinical studies, and the upcoming Access365™ Home Ventilation Solution, anticipated to launch in early 2025. This new home ventilation solution aims to improve patient quality of life and reduce hospital readmissions for patients with respiratory diseases.
Financially, Vapotherm has made considerable strides in improving profitability. For example, in the third quarter of 2023, the company reported a net revenue increase of 12.0% over the previous year, attributed to rising capital and disposable demand, especially in international markets. Furthermore, gross profit and margin saw improvements, owing to effective inventory management and increased production efficiencies.
Despite challenges, such as delisting from the New York Stock Exchange and transitioning to the OTCQX Market, the company remains steadfast in its commitment to enhancing patient lives and maintaining significant market presence. Partnerships like the one with Onymos to develop a respiratory digital platform further underscore Vapotherm's dedication to innovation and improved patient outcomes.
Vapotherm, Inc. (NYSE: VAPO) plans to release its financial results for Q2 2021 after market close on August 9, 2021. The management will host a conference call at 4:30 p.m. ET to discuss these results and recent developments. Vapotherm is a medical technology company focusing on high velocity therapy for patients with respiratory distress. This innovative, non-invasive technology has treated over 2.8 million patients, providing comfortable support and reducing risks associated with traditional therapies.
Vapotherm, Inc. (NYSE: VAPO) announced its first investor day on June 23, 2021, starting at 10:00 AM ET. The event will take place at their Exeter, New Hampshire facilities, with a live webcast option available. Vapotherm specializes in high velocity therapy products that aid patients experiencing respiratory distress, having treated over 2.8 million patients. A replay of the webcast will be accessible for 90 days on their investor website. This initiative aims to enhance investor engagement, showcasing the company's innovative non-invasive respiratory technologies.
Vapotherm (NYSE: VAPO) announced its management will participate in the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 9:00 am ET via webcast. Investors can access the live presentation through a link available on Vapotherm's website. A replay will be available for 90 days in the Event Archive section. Vapotherm specializes in high velocity therapy for respiratory distress, having treated over 2.8 million patients. For further information, visit their Investor Relations website.
Vapotherm (NYSE: VAPO), a medical technology company specializing in high velocity therapy products for respiratory distress, will participate in the Bank of America Securities 2021 Health Care Conference on May 12, 2021, via webcast. The management team will engage in a fireside chat at 11:45 AM ET, accessible at this link. A replay will be available for 90 days on Vapotherm’s Investor website. The company has treated over 2.6 million patients with its innovative non-invasive respiratory technologies.
Vapotherm (NYSE: VAPO) reported a remarkable 69% revenue increase to $32.3 million in Q1 2021 compared to Q1 2020. The global installed base of Precision Flow Hi-VNI systems surged by 73%, boosting gross margins to 53.1%. Adjusted EBITDA loss improved to $5.2 million, down from $10.2 million year-over-year. Operating expenses rose to $26.9 million as the company invests in growth and R&D. The company anticipates full-year revenue between $82 million and $88 million, despite challenges due to COVID-19-related demand fluctuations. Cash reserves were reported at $93.8 million.
Vapotherm (NYSE: VAPO), a leading medical technology company, will announce its first-quarter 2021 financial results post-market on May 5, 2021. The management team will host a conference call at 4:30 p.m. ET to discuss the results and recent business updates. Investors can join by calling specific numbers or via a live webcast. Vapotherm specializes in high-velocity therapy products aimed at treating respiratory distress, with over 2.6 million patients treated using their systems. For more details, visit their investor relations website.
Vapotherm, a global medical technology firm, announced its fourth quarter and fiscal year 2020 results, reporting a net revenue of $40.9 million for Q4, a 214.4% increase year-over-year. Fiscal year 2020 net revenue reached $125.7 million, a growth of 161.4% from 2019. Gross margins improved to 50.6% in Q4 and 50.1% for the year. Despite these gains, the company reported a net loss of $17.2 million in Q4 and $51.5 million for the year. The company anticipates revenue between $82 million and $88 million for 2021, reflecting significant post-COVID demand fluctuations.
Vapotherm, a medical technology company listed on NYSE as VAPO, announced participation in a Fireside Chat at the BTIG Virtual MedTech Conference on February 17, 2021. The management team will present at 9:00 am Eastern Time, with live access via this link. A replay will be available for 90 days on Vapotherm's Investor website. The company specializes in high-velocity therapy products for respiratory distress, having treated over 2.5 million patients, enhancing non-invasive ventilatory support.
Vapotherm, Inc. (NYSE: VAPO) will release its fourth-quarter and fiscal year 2020 financial results on February 24, 2021. The management team will host a conference call at 4:30 p.m. ET to discuss these results and recent developments. Vapotherm specializes in high-velocity therapy products for patients with respiratory distress and has treated over 2.5 million patients. Investors can listen to the call via phone or a live webcast on the company's website, with a replay available for a limited time.
Vapotherm (NYSE: VAPO) announced preliminary unaudited revenue results for Q4 and full year 2020. Q4 revenue is projected at $40.6 million, a 212% increase from $13.0 million in Q4 2019. For the full year, expected revenue is $125.4 million, a 161% rise compared to $48.1 million in 2019. The growth is attributed to increased demand during the COVID-19 pandemic and expanded production capabilities. Vapotherm’s installed base of Precision Flow systems significantly increased, with better disposable utilization rates. Full financial results will be released in late February 2021.
FAQ
What is the current stock price of VAPOTHERM (VAPO)?
What is the market cap of VAPOTHERM (VAPO)?
What does Vapotherm, Inc. specialize in?
What are Vapotherm's core products?
How many patients have been treated with Vapotherm's technology?
Where is Vapotherm headquartered?
What financial progress has Vapotherm made recently?
What is Vapotherm's Access365 Home Ventilation Solution?
What challenges has Vapotherm faced recently?
What recent partnerships has Vapotherm formed?
What upcoming product launches does Vapotherm have?
How does Vapotherm's high-velocity therapy benefit patients?
